A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.Drew Rasco, Yifan Zhai, Yuefen Tang et al.|Journal of Clinical Oncology|2019Cited by 27
A phase I study of a novel IAP inhibitor APG-1387 as a monotherapy or in combination with pembrolizumab in treatments of patients with advanced solid tumors.Drew Rasco, Yifan Zhai, Yufeng Li et al.|Journal of Clinical Oncology|2019Cited by 11
Phase Ib study of a novel bivalent IAP antagonist APG-1387 in combination of pembrolizumab for patients with advanced solid tumors.Drew Rasco, Yifan Zhai, Dajun Yang et al.|Journal of Clinical Oncology|2020Cited by 6